超声造影联合声触诊组织量化技术鉴别肝血管瘤与肝细胞癌价值研究*

doi:10.3969/j.issn.1672-5069.2022.04.030

Abstract

Abstract: Objective The aim of this study was to evaluate the value of contrast ultrasonography (CEUS) and virtual touch tissue quantification (VTQ) in differentiating hepatic hemangioma from hepatocellular carcinoma (HCC). Methods 93 patients with intrahepatic space-occupying lesions were encountered in our hospital between April 2018 and April 2021, and all underwent CEUS and VTQ check-up. The CEUS parameters including start enhancement time, peak enhancement time and peak intensity, and the shear wave velocity (SWV) of intrahepatic foci, surrounding tissues and SWV ratio of foci/surrounding tissue obtained by VTQ were recorded. Thediagnostic efficacy was determined by ROC analysis. Results Out of our series, the hepatic hemangioma was found in 40 cases, and HCC in 53 cases based on CT/MRI scan or post-operational histopathological examination; the onset enhancement time and peak enhancement time in patients with HCC were (8.2±1.2) s and (16.7±3.3) s, significantly shorter than [(15.9±5.0) s and (45.7±15.4) s, respectively, P < 0.05] in patients with hepatic hemangioma; the SWV of hepatic foci, the SWV of surrounding tissues and SWV ratio in patients with HCC were (2.7±0.9), (2.0±0.8) and (1.8±0.7), significantly greater than [(1.5±0.4), (1.4±0.6) and (1.1±0.3), respectively, P＜0.05] in patients with hepatic hemangioma; the ROC analysis showed that the onset enhancement time, peak enhancement time, the SWV of hepatic foci, the SWV of surrounding tissues and SWV ratio all had some diagnostic efficacy with the AUC of 0.754, 0.818, 0.758, 0.802 and 0.809, respectively; we set the onset enhancement time ≤12.080 s, the peak enhancement time≤26.530 s, the SWV of hepatic foci≥2.015 m/s, the SWV of surrounding tissues ≥1.920 m/s and SWV ratio ≥1.280 as the optimal cut-off-value, the HCC was diagnosed in 48 cases when any one of the five parameter meeting, with sensitivity of 0.906, specificity of 0.950, accuracy of 0.925, positive predictive value of 0.960 and negative predictive value of 0.884. Conclusion There are significant differences in CEUS and VTQ results between HCC and hepatic hemangioma, by which the clinicians could make differentiation of benign and malignant intrahepatic lesions.

Key words: Hepatoma, Hepatic hemangioma, Contrast-enhanced ultrasound, Virtual touch tissue quantification, Diagnosis

Wang Jing, Zhang Jie, Zhao Jing. Differentiation of hepatic hemangioma from hepatocellular carcinoma by contrast ultrasonography and virtual touch tissue quantification: An analysis of 93 cases[J]. Journal of Practical Hepatology, 2022, 25(4): 575-578.

References

[1] Dhanasekaran R, Felsher WD. A tale of two complications of obesity: Nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). Hepatology, 2019, 70(3):1056-1058.
[2] Facp M, Go TS, Kithier K, et al. Proceedings: Primary liver cancer. A review of the clinical features, blood groups, serum enzymes, therapy, and survival of 65 cases. Cancer, 2015, 33(2):574-582.
[3] Valery PC, Laversanne M, Clark P J, et al. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology, 2018, 67(2):600-611.
[4] Li R, Tang C, Cai P, et al. Comparison of CT and contrast-enhanced ultrasound findings in hepatic angiomyolipoma with pathological correlations. Abdom Radiol, 2016, 41(2):248-256.
[5] Wang B, Ye Z, Chen Y, et al. Hepatic angiomyolipomas: Ultrasonic characteristics of 25 patients from a single center. Ultrasound Med Biol, 2015, 41(2):393-400.
[6] 袁元, 魏毅, 唐鹤菡,等. 钆塞酸二钠肝脏MRI多动脉期增强扫描评价肝血管解剖与CTA的对照研究. 中华放射学杂志, 2019, 53(12):1086-1090.
[7] 吴长君, 张光晨, 孟巍,等. 声触诊组织量化技术鉴别乳腺良恶性肿块的价值. 中华超声影像学杂志 2011, 20(11):965-969.
[8] 肖莉莉, 赵雅萍, 高凌云,等. 声触诊组织量化技术对甲状腺实性小结节良恶性的鉴别诊断价值. 中华超声影像学杂志, 2012, 21(9):771-774.
[9] Sakamoto Y, Kokudo N, Watadani T, et al. Proposal of size-based surgical indication criteria for liver hemangioma based on a nationwide survey in Japan. J Hepatobiliary Pancreat Sci,2017, 24(7):417-425.
[10] Renzulli M, Ricciardi D, Clemente A, et al. Unexpected newborns in the liver : Hemangiomatosis onset after hepatic resection of a giant cavernous hemangioma. Acta gastroenterol Belg, 2019, 82(3):454-455.
[11] Perfahl H, Jain HV, Joshi T, et al. Hybrid modelling of transarterial chemoembolisation therapies (TACE) for hepatocellular carcinoma (HCC). Sci Rep, 2020, 10(1):10571-10571.
[12] Li K, Su ZZ, Xu EJ, et al. Improvement of ablative margins by the intraoperative use of CEUS-CT/MR image fusion in hepatocellular carcinoma. Bmc Cancer, 2016, 16(1):1-9.
[13] Jin B, Lin M, You M, et al. Microbubble embedded with upconversion nanoparticles as a bimodal contrast agent for fluorescence and ultrasound imaging. Nanotechnology, 2015, 26(34):345601-345601.
[14] Wu M, Li L, Wang J, et al. Contrast-enhanced us for characterization of focal liver lesions: A comprehensive meta-analysis. Eur Radiol, 2018, 28(5):2077-2088.
[15] Smajerova M, Petrasova H, Little J, et al. Contrast-enhanced ultrasonography in the evaluation of incidental focal liver lesions: A cost-effectiveness analysis. World J Gastroenterol, 2016, 22(38):8605-8614.
[16] 雒大健, 全艳, 张志勇. 超声造影与彩色多普勒超声在肝实质性肿块诊断中的对比研究. 中国超声医学杂志, 2018, 34(8):35-39.
[17] Cho SH, Lee JY, Han JK, et al. Acoustic radiation force impulse elastography for the evaluation of focal solid hepatic lesions: Preliminary findings. Ultrasound Med Biol, 2010, 36(2):202-208.
[18] Guo LH, Wang SJ, Xu HX, et al. Differentiation of benign and malignant focal liver lesions: Value of virtual touch tissue quantification of acoustic radiation force impulse elastography. Med Oncol, 2015, 32(3):68-68.
[19] Ming TS, Ping Z, Ying Q, et al. Usefulness of acoustic radiation force impulse imaging in the differential diagnosis of benign and malignant liver lesions. Acad Radiol, 2011, 18(7):810-815.
[20] 邓砚之, 徐晓红. 超声造影和声触诊组织量化技术对肝脏良、恶性病变的诊断价值. 中华临床医师杂志(电子版), 2013, 7(7):70-72.

Differentiation of hepatic hemangioma from hepatocellular carcinoma by contrast ultrasonography and virtual touch tissue quantification: An analysis of 93 cases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Mo Jinying, Yu Xi, Yu Xueping, et al. Diagnostic performance of FibroTouch scan in identifying liver fibrosis in hepatitis B virus carriers [J]. Journal of Practical Hepatology, 2022, 25(4): 480-483.
[2]	Luo Zhenzhen, Tian Haiying, Ge Jianhua, et al. Clinical evaluation of liver fibrosis by serum N-oligosaccharide and bile acid levels and liver stiffness measurement combination in patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2022, 25(4): 504-507.
[3]	Fu Lihong, Gao Yueqiu, Wang XiaoLin, et al. Liver pathological features of patients with drug-induced liver injury: An analysis of 38 cases [J]. Journal of Practical Hepatology, 2022, 25(4): 512-516.
[4]	Tang Lei, Peng Lei, Ye Jun, et al. Multivariate analysis of liver fibrosis progress in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2022, 25(4): 538-541.
[5]	Li Fang, Wang Yansen, Weng Luxin. Diagnostic performance of liver parenchymal texture feature quantification by high-frequency ultrasonography and serum AFP-L3 levels in the evaluation of liver function classification in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(4): 542-545.
[6]	Wang Baofeng, Ma Yangao, Li Yi, et al. Diagnostic efficacy of GD-EOB-DTPA enhanced MRI in differentiation of primary liver cancer from nodular regenerative hyperplasia of liver in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(4): 554-557.
[7]	Liu Hao, Zhou Feifei, Sun Haokai, et al. CBCT-based 3D reconstruction technique in the identification of blood supplying arteries during TACE operation for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2022, 25(4): 563-566.
[8]	Wang Yuanping, Zheng Lulu, Zhang Guangliang. A pilot study of MR and 4DCT images in the delineation of target area in patients with primary liver cancer undergoing first radiotherapy [J]. Journal of Practical Hepatology, 2022, 25(4): 567-570.
[9]	Sun Xiangzheng, Lu Wei, Li Ruoman. Differential diagnosis of hepatic hemangioma from liver metastasis by enhanced multi-slice spiral CT [J]. Journal of Practical Hepatology, 2022, 25(4): 579-582.
[10]	Zong Jinjuan, Zhou Ming, Shi Jiale. Application of computed tomography angiography and ultrasonography in preoperative assessment of hepatic blood vessels in patients undergoing liver transplantation [J]. Journal of Practical Hepatology, 2022, 25(4): 583-586.
[11]	Wei Bowen, Ren Zheng, Zhang Liang, et al. Enhanced CT scanning in evaluating residual tumor in patients with primary liver cancer after TACE theapy [J]. Journal of Practical Hepatology, 2022, 25(4): 603-604.
[12]	Jin Panpan, Zhang Lingyi. PIVKA-II: a new biological marker in diagnosis of patients with hepatitis B-related hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2022, 25(4): 605-608.
[13]	Guo Yuecheng, Lu Lungen. Diagnosis and management of liver fibrosis [J]. Journal of Practical Hepatology, 2022, 25(3): 305-308.
[14]	Li Chunhua, Li Zhongxin, Zhang Chunlei, et al. Diagnostic performance of serum FGF-21, PDGF-BB and FBRS levels on significant liver fibrosis in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2022, 25(3): 347-350.
[15]	Zhong Huan, Ye Wei. Platelet count/spleen length ratio in predicting gastroesophageal varices in patients with primary biliary cholangitis [J]. Journal of Practical Hepatology, 2022, 25(3): 363-366.